{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:57Z","timestamp":1791868977817,"version":"4.3.4"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background.<\/jats:title><jats:p>Biological treatments, chemoimmunotherapy, and radiotherapy are associated with excellent disease control in both gastric and extragastric mucosa-associated lymphoid tissue (MALT) lymphomas. Systemic treatment approaches with both oral and i.v. agents are being increasingly studied, not only for patients with disseminated MALT lymphoma, but also for those with localized disease. To date, however, recommendations for the use of available systemic modalities have not been clearly defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods.<\/jats:title><jats:p>The present report reviews the current data on systemic treatment options for patients with MALT lymphoma and provides recommendations for their use in everyday practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Different chemotherapeutic agents, including anthracyclines, alkylators, and purine analogs, have been successfully tested in patients with MALT lymphoma. Reducing side effects while maintaining efficacy should be the main goal in treating these indolent lymphomas. From the data from the largest trial performed to date, the combination of chlorambucil plus rituximab (R) appears to be active as first-line treatment. Similarly, R-bendamustine also seems to be highly effective, but a longer follow-up period is needed. R-monotherapy results in lower remission rates, but seems a suitable option for less fit patients. New immunotherapeutic agents such as lenalidomide (with or without rituximab) or clarithromycin show solid activity but have not yet been validated in larger collectives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Patients with MALT lymphoma should be treated within prospective trials to further define optimal therapeutic strategies. Systemic treatment is a reasonable option with potentially curative intent in everyday practice. Based on the efficacy and safety data from available studies, the present review provides recommendations for the use of systemic strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice:<\/jats:title><jats:p>In view of the biology of MALT lymphoma with trafficking of cells within various mucosal structures, systemic treatment strategies are increasingly being used not only in advanced but also localized MALT lymphoma. In the past, different chemotherapeutic agents, including anthracyclines, alkylators, and purine analogs, have been tested successfully. However, modern regimens concentrate on reducing side effects because of the indolent nature of this distinct disease. As outlined in this review and based on recent data, chlorambucil plus rituximab (R) may be considered one standard treatment within this setting. In addition, R-bendamustine seems to be a very promising combination. According to recent trends, however, \u201cchemo-free\u201d approaches (i.e., antibiotics with immunomodulatory effects [clarithromycin]) or other immunotherapies (lenalidomide \u00b1R) may be important therapeutic approaches in the near future.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0109","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T02:25:08Z","timestamp":1436408708000},"page":"915-925","source":"Crossref","is-referenced-by-count":33,"title":["Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature"],"prefix":"10.1093","volume":"20","author":[{"given":"Barbara","family":"Kiesewetter","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine I, Medical University Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine I, Medical University Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"key":"2021122309363649900_B1","first-page":"214","volume-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"Isaacson","year":"2008"},{"key":"2021122309363649900_B2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0140-6736(91)92035-Z","article-title":"Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma","volume":"338","author":"Wotherspoon","year":"1991","journal-title":"Lancet"},{"key":"2021122309363649900_B3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gut.53.1.34","article-title":"Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: Experience from a large prospective series","volume":"53","author":"Fischbach","year":"2004","journal-title":"Gut"},{"key":"2021122309363649900_B4","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: Final results of an international phase II trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309363649900_B5","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: A multicenter prospective trial","volume":"98","author":"Ferreri","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021122309363649900_B6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: A review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"key":"2021122309363649900_B7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: A study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B8","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122309363649900_B9","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"key":"2021122309363649900_B10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijrobp.2009.04.018","article-title":"Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma)","volume":"77","author":"Son","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309363649900_B11","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122309363649900_B12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000098555","article-title":"Activity of rituximab plus cyclophosphamide, doxorubicin\/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma","volume":"70","author":"Raderer","year":"2006","journal-title":"Oncology"},{"key":"2021122309363649900_B13","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1200\/JCO.2004.00.8532","article-title":"Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma","volume":"23","author":"Raderer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309363649900_B14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.leukres.2009.04.003","article-title":"2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma","volume":"34","author":"Orciuolo","year":"2010","journal-title":"Leuk Res"},{"key":"2021122309363649900_B15","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/annonc\/mdg492","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)","volume":"14","author":"W\u00f6hrer","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-Year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309363649900_B17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10428194.2012.729832","article-title":"Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: A monocentric non-randomized observational study","volume":"54","author":"L\u00e9vy","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2021122309363649900_B18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"key":"2021122309363649900_B19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10428190903431820","article-title":"Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: Clinical, histological, and molecular follow-up","volume":"51","author":"L\u00e9vy","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2021122309363649900_B20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00277-007-0301-y","article-title":"Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas","volume":"86","author":"Rigacci","year":"2007","journal-title":"Ann Hematol"},{"key":"2021122309363649900_B21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: Clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"key":"2021122309363649900_B22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ophtha.2006.01.057","article-title":"Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit","volume":"113","author":"Ben Simon","year":"2006","journal-title":"Ophthalmology"},{"key":"2021122309363649900_B23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","article-title":"Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: Results of the international randomised LY03 trial","volume":"144","author":"Hancock","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122309363649900_B24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"2021122309363649900_B25","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2105","article-title":"Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone 139","volume":"32","author":"Aguiar-Bujanda","year":"2014","journal-title":"Hematol Oncol"},{"key":"2021122309363649900_B26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2021122309363649900_B27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3691.3691","article-title":"Final results of a multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008-01)","volume-title":"Paper presented at: ASH 2012 Annual Meeting, 2012 (abstract 3691)","author":"Salar"},{"key":"2021122309363649900_B28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-013-1865-3","article-title":"Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"93","author":"Kiesewetter","year":"2014","journal-title":"Ann Hematol"},{"key":"2021122309363649900_B29","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: A phase II study","volume":"20","author":"J\u00e4ger","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309363649900_B30","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdl126","article-title":"Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 Year follow-up of a phase II trial","volume":"17","author":"J\u00e4ger","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.2012.072587","article-title":"Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: A phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie","volume":"98","author":"Troch","year":"2013","journal-title":"Haematologica"},{"key":"2021122309363649900_B32","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"key":"2021122309363649900_B33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MO:22:1:057","article-title":"Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: Results of a controlled clinical trial","volume":"22","author":"Avil\u00e9s","year":"2005","journal-title":"Med Oncol"},{"key":"2021122309363649900_B34","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"key":"2021122309363649900_B35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdm529","article-title":"Low-grade mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG)","volume":"19","author":"Papaxoinis","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B36","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cncr.20237","article-title":"Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma","volume":"100","author":"Zinzani","year":"2004","journal-title":"Cancer"},{"key":"2021122309363649900_B37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hon.2039","article-title":"Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens","volume":"31","author":"Zinzani","year":"2013","journal-title":"Hematol Oncol"},{"key":"2021122309363649900_B38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10428190701784714","article-title":"Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma","volume":"49","author":"Economopoulos","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122309363649900_B39","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"2021122309363649900_B40","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309363649900_B41","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428190701457949","article-title":"Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma","volume":"48","author":"Lossos","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2021122309363649900_B42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"key":"2021122309363649900_B43","first-page":"1578","article-title":"Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa","volume":"90","author":"Ferreri","year":"2005","journal-title":"Haematologica"},{"key":"2021122309363649900_B44","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2021122309363649900_B45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: Response and follow-up in 16 patients","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00277-011-1387-9","article-title":"Plasmacytic differentiation in MALT lymphomas following treatment with rituximab","volume":"91","author":"Troch","year":"2012","journal-title":"Ann Hematol"},{"key":"2021122309363649900_B47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10428194.2010.534519","article-title":"90Y-ibritumomab-tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma","volume":"52","author":"Hoffmann","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2021122309363649900_B48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2078","article-title":"Efficacy of 90Yttrium-ibritumomab-tiuxetan in relapsed\/refractory extranodal marginal-zone lymphoma","volume":"32","author":"Vanazzi","year":"2014","journal-title":"Hematol Oncol"},{"key":"2021122309363649900_B49","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-014-2042-z","article-title":"Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: A single-center analysis","volume":"93","author":"W\u00f6hrer","year":"2014","journal-title":"Ann Hematol"},{"key":"2021122309363649900_B50","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2008.001537","article-title":"A phase II study of bortezomib in patients with MALT lymphoma","volume":"94","author":"Troch","year":"2009","journal-title":"Haematologica"},{"key":"2021122309363649900_B51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","author":"Conconi","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B52","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/annonc\/mdp349","article-title":"Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"20","author":"Troch","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"2021122309363649900_B54","article-title":"A phase II study of rituximab plus lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)","volume-title":"Paper presented at: 19th Congress of EHA, 2014 (abstract 651)","author":"Raderer"},{"key":"2021122309363649900_B55","first-page":"133","article-title":"Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production","volume":"25","author":"Aoki","year":"2005","journal-title":"Anticancer Res"},{"key":"2021122309363649900_B56","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/47.6.867","article-title":"The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages","volume":"47","author":"Kurdowska","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2021122309363649900_B57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3835(98)00110-4","article-title":"Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic","volume":"131","author":"Yatsunami","year":"1998","journal-title":"Cancer Lett"},{"key":"2021122309363649900_B58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/sonc.2003.50044","article-title":"Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone","volume":"30","author":"Coleman","year":"2003","journal-title":"Semin Oncol"},{"key":"2021122309363649900_B59","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky","year":"2008","journal-title":"Blood"},{"key":"2021122309363649900_B60","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","article-title":"Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: Final results of a single-centre phase II trial","volume":"150","author":"Govi","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122309363649900_B61","article-title":"High-dose clarithromycin is a feasible and active monotherapy for patients with relapsed\/ refractory extranodal marginal zone lymphoma [EMZL]: Results from the \u201cHD-K\u201d phase II trial","volume-title":"Paper presented at: 19th Congress of EHA, 2014 (abstract 442)","author":"Ferreri"},{"key":"2021122309363649900_B62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br J Haematol"},{"issue":"suppl 6","key":"2021122309363649900_B63","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309363649900_B64","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","article-title":"EGILS consensus report: Gastric extranodal marginal zone B-cell lymphoma of MALT","volume":"60","author":"Ruskon\u00e9-Fourmestraux","year":"2011","journal-title":"Gut"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/8\/915\/41869937\/oncolo_20_8_915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/8\/915\/41869937\/oncolo_20_8_915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:04:08Z","timestamp":1748487848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/8\/915\/6399684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":64,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,7,8]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0109","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,8,1]]},"published":{"date-parts":[[2015,7,8]]}}}